[go: up one dir, main page]

PE20141585A1 - Composicion farmaceutica estabilizada a base de un compuesto no petidico - Google Patents

Composicion farmaceutica estabilizada a base de un compuesto no petidico

Info

Publication number
PE20141585A1
PE20141585A1 PE2014000933A PE2014000933A PE20141585A1 PE 20141585 A1 PE20141585 A1 PE 20141585A1 PE 2014000933 A PE2014000933 A PE 2014000933A PE 2014000933 A PE2014000933 A PE 2014000933A PE 20141585 A1 PE20141585 A1 PE 20141585A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
pyrrol
pyridin
composition
content
Prior art date
Application number
PE2014000933A
Other languages
English (en)
Inventor
Yasuhiro Hiraishi
Muneo Nonomura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41327301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141585(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20141585A1 publication Critical patent/PE20141585A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: (I) UN INGREDIENTE FARMACEUTICAMENTE ACTIVO NO PEPTIDICO QUE TIENE UN GRUPO AMINO PRIMARIO O SECUNDARIO SELECCIONADO DE 1-[5-(2-FLUOROFENIL)-1-(PIRIDIN-3-ILSUFONIL)-1H-PIRROL-3-IL]-N-METILMETANAMINA; N-METIL-1-[5-(2-METILFENIL)-1-(PIRIDIN-3-ILSULFONIL)-1H-PIRROL-3-IL]METANAMINA; O 1-[4-FLUORO-5-(2-FLUOROPIRIDIN-3-IL)-1-(PIRIDIN-3-ILSULFONIL)-1H-PIRROL-3-IL]-N-METILMETANAMINA O SALES DE LOS MISMOS, CON UN CONTENIDO DE 0,39 - 26,72% EN LA COMPOSICION; (II) UN EXCIPIENTE SELECCIONADO DE MANITOL, CROSCARMELOSA SODICA, HIDROXIPROPILCELULOSA, POLIETILENGLICOL, ENTRE OTROS, CON UN CONTENIDO DE 63,28 - 99,35% EN LA COMPOSICION; Y (III) UN COMPUESTO ACIDICO COMO ESTABILIZADOR TAL COMO ACIDO FUMARICO, CON UN CONTENIDO DE 0,05 - 10% EN LA COMPOSICION
PE2014000933A 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada a base de un compuesto no petidico PE20141585A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008194219 2008-07-28

Publications (1)

Publication Number Publication Date
PE20141585A1 true PE20141585A1 (es) 2014-11-13

Family

ID=41327301

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2014000508A PE20140977A1 (es) 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada a base de un compuesto no peptidico
PE2014000933A PE20141585A1 (es) 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada a base de un compuesto no petidico
PE2011000089A PE20110591A1 (es) 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada a base de un compuesto no peptidico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2014000508A PE20140977A1 (es) 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada a base de un compuesto no peptidico

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011000089A PE20110591A1 (es) 2008-07-28 2009-07-27 Composicion farmaceutica estabilizada a base de un compuesto no peptidico

Country Status (29)

Country Link
US (2) US9186411B2 (es)
EP (2) EP2309985B1 (es)
JP (2) JP5295356B2 (es)
KR (1) KR20110042334A (es)
CN (3) CN102743330B (es)
AR (1) AR072842A1 (es)
AU (1) AU2009277443A1 (es)
BR (1) BRPI0916689A2 (es)
CA (2) CA2732243C (es)
CL (1) CL2011000170A1 (es)
CO (1) CO6290638A2 (es)
CR (1) CR20110110A (es)
DO (2) DOP2011000033A (es)
EA (2) EA201201451A1 (es)
EC (1) ECSP11010855A (es)
ES (2) ES2669592T3 (es)
GE (2) GEP20146166B (es)
IL (2) IL210735A0 (es)
MA (1) MA32556B1 (es)
MX (1) MX2011000757A (es)
MY (2) MY156305A (es)
NZ (2) NZ602592A (es)
PE (3) PE20140977A1 (es)
SG (1) SG186685A1 (es)
TW (2) TW201010992A (es)
UA (1) UA103332C2 (es)
UY (1) UY32008A (es)
WO (1) WO2010013823A2 (es)
ZA (1) ZA201101198B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254322B (zh) * 2012-02-15 2017-06-13 武田药品工业株式会社 片剂
EP2866788B1 (en) * 2012-06-27 2020-12-16 Takeda Pharmaceutical Company Limited Liquid preparations of amines and organic acids stabilized by salts
MX345435B (es) * 2012-09-19 2017-01-30 Taiho Pharmaceutical Co Ltd Composicion farmaceutica para la administracion oral con disolucion y/o absorcion mejorada.
EP2968695A1 (en) * 2013-03-14 2016-01-20 Allergan, Inc. Polymer system for securing implants in syringe needles
CN105330647A (zh) * 2014-08-14 2016-02-17 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
CN105985278A (zh) * 2015-01-27 2016-10-05 江苏柯菲平医药股份有限公司 吡咯磺酰类衍生物、其制备方法及其在医药上的应用
MA41850A (fr) 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co Nouvelles utilisations pharmaceutiques
CR20180119A (es) 2015-07-30 2018-03-21 Takeda Pharmaceuticals Co Tableta
CN105106203B (zh) * 2015-08-17 2019-04-05 江苏豪森药业集团有限公司 富马酸沃诺拉赞的药物组合物及其制备方法
CN105030720B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶片及其制备方法
CN105030725B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶组合物及其制备方法
CN107224438B (zh) * 2016-03-25 2021-04-06 江苏豪森药业集团有限公司 富马酸沃诺拉赞药物组合物
WO2018071233A1 (en) * 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
CN106580903B (zh) * 2016-11-17 2019-12-13 江苏豪森药业集团有限公司 罗红霉素缓释药物组合物
CN106860852A (zh) * 2017-02-17 2017-06-20 王清华 一种用于结合治疗胃病的粘液西药
MX2019014201A (es) 2017-05-31 2020-01-23 Boehringer Ingelheim Int Composicion farmaceutica y forma de dosificacion farmaceutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenza mida, proceso para su preparacion, metodos de tratamiento y usos de las mismas.
MY200542A (en) * 2017-07-10 2024-01-02 Takeda Pharmaceuticals Co Preparation comprising vonoprazan
CN108558831B (zh) * 2018-06-08 2021-07-27 上海璃道医药科技有限公司 取代吡咯-4-烷基胺类化合物及其用途
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
CN109288722B (zh) * 2018-11-09 2021-03-30 伯德创研(广州)生物科技有限公司 一种变色修正肤色的粉底及其制备方法
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
LT3965741T (lt) * 2020-04-24 2023-09-11 Dr. Falk Pharma Gmbh Sisteminė piridinono darinio kompozicija , skirta sergant celiakija
CN111973565A (zh) * 2020-07-07 2020-11-24 南京海纳医药科技股份有限公司 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法
CN114053239A (zh) * 2020-08-01 2022-02-18 吉林汇康制药有限公司 一种富马酸伏诺拉生药物组合物及制备方法
CN111943932B (zh) * 2020-08-06 2023-07-14 四川国康药业有限公司 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途
MX2023003783A (es) * 2020-10-01 2023-04-26 Imago Biosciences Inc Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a.
CN114853728B (zh) * 2022-05-07 2023-11-07 四川制药制剂有限公司 一种富马酸伏诺拉生片及其制备方法
CN115364065B (zh) * 2022-08-23 2024-03-15 宁波高新区美诺华医药创新研究院有限公司 富马酸伏诺拉生片
CN115944743B (zh) * 2023-01-18 2025-08-08 山东诚成医药科技有限公司 一种富马酸伏诺拉生组合物及其制备方法
WO2025064381A1 (en) * 2023-09-18 2025-03-27 Phathom Pharmaceuticals Inc. Method for preparing vonoprazan with reduced nitrosamine
CN119970680B (zh) * 2023-11-10 2025-10-03 中国人民解放军军事科学院军事医学研究院 一种秋水仙碱缓释微丸及其制备方法
CN117462507B (zh) * 2023-12-28 2024-03-15 山东齐都药业有限公司 富马酸伏诺拉生药物组合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2844351B2 (ja) 1989-07-13 1999-01-06 株式会社科薬 安定なポリミキシン系抗生物質水性溶液
US5422362A (en) 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
FR2745500B1 (fr) 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
US5834503A (en) 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
FR2752162B1 (fr) 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
JP4730985B2 (ja) 1997-09-10 2011-07-20 武田薬品工業株式会社 安定化された医薬製剤
EP0901787B1 (en) * 1997-09-10 2003-05-28 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
WO2001070746A1 (en) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
WO2003011296A1 (fr) 2001-07-30 2003-02-13 Mitsubishi Pharma Corporation Preparations pharmaceutiques stables contenant comme principe actif des derives de l'acide aminobenzenesulphonique
CN1571664A (zh) 2001-10-17 2005-01-26 久光制药株式会社 经皮吸收型制剂
WO2003074076A2 (en) 2002-02-28 2003-09-12 The Penn State Research Foundation Periocular drug delivery for diabetic retinopathy
PT1485094E (pt) 2002-03-07 2012-10-09 Boehringer Ingelheim Int Forma de administração por via oral para 3-[(2-{[4- (hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil- 1h-benzimidazole-5-carbonil)-piridin-2-il-amino]-propionato de etilo ou os seus sais
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
DE10233108A1 (de) 2002-07-20 2004-01-29 Krewel Meuselbach Gmbh Retardiertes Schmerzmittel enthaltend Tilidin und ein Lichtschutzmittel
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
TWI398273B (zh) 2003-07-18 2013-06-11 Santarus Inc 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
JP2005263788A (ja) 2004-02-17 2005-09-29 Sankyo Co Ltd インドリン化合物を含有する安定化された医薬組成物
KR20120064735A (ko) 2004-04-01 2012-06-19 아지노모토 가부시키가이샤 나테글리니드 함유 제제
JP2006001912A (ja) 2004-06-21 2006-01-05 Chugai Pharmaceut Co Ltd タンパク質製剤の安定化方法
EP2336107B1 (en) 2004-09-30 2015-09-23 Takeda Pharmaceutical Company Limited Proton pump inhibitors
EP1799211A1 (en) 2004-10-05 2007-06-27 Altana Pharma AG Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
WO2007023931A1 (ja) * 2005-08-25 2007-03-01 Kyowa Hakko Kogyo Co., Ltd. 血中アルコール濃度上昇抑制用組成物
PT2327692E (pt) * 2005-08-30 2012-10-11 Takeda Pharmaceutical Derivados de 1h-pirrole substituídos com 1-heterociclilsulfonilo, 2-aminometilo, 5-(hetero)arilo como inibidores da secreção ácida
BRPI0620788A2 (pt) * 2005-12-28 2011-11-22 Takeda Pharmaceutical preparação sólida
CN101516367A (zh) 2006-09-15 2009-08-26 安斯泰来制药有限公司 对光稳定的雷莫司琼的固态医药组合物
JP5074052B2 (ja) 2007-02-13 2012-11-14 有限会社愛和ライト 遊技機
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
EP2196459B1 (en) 2007-09-28 2016-11-02 Takeda Pharmaceutical Company Limited 5-membered heterocyclic compound
TW200920366A (en) 2007-09-28 2009-05-16 Takeda Pharmaceutical 5-membered heterocyclic compound
EP2226075A1 (en) 2007-11-22 2010-09-08 The University of Tokyo Material for preventing tissue adhesion and material for preventing joint contracture

Also Published As

Publication number Publication date
AR072842A1 (es) 2010-09-22
EP2309985A2 (en) 2011-04-20
JP5593363B2 (ja) 2014-09-24
CN102743330B (zh) 2016-03-23
IL210735A0 (en) 2011-03-31
MY169461A (en) 2019-04-11
GEP20146122B (en) 2014-07-25
CO6290638A2 (es) 2011-06-20
EA201170272A1 (ru) 2011-10-31
CA2732243C (en) 2016-11-29
CA2936400A1 (en) 2010-02-04
CN102164581A (zh) 2011-08-24
CA2936400C (en) 2018-03-27
JP2011529445A (ja) 2011-12-08
UA103332C2 (ru) 2013-10-10
TW201431552A (zh) 2014-08-16
JP5295356B2 (ja) 2013-09-18
SG186685A1 (en) 2013-01-30
US9186411B2 (en) 2015-11-17
MX2011000757A (es) 2011-02-24
NZ602592A (en) 2014-01-31
ECSP11010855A (es) 2011-03-31
PE20140977A1 (es) 2014-08-20
KR20110042334A (ko) 2011-04-26
NZ591344A (en) 2013-03-28
ES2669592T3 (es) 2018-05-28
EP2564833B1 (en) 2017-12-20
EP2564833A1 (en) 2013-03-06
CN104784180A (zh) 2015-07-22
TW201010992A (en) 2010-03-16
UY32008A (es) 2010-02-26
CN102743330A (zh) 2012-10-24
CR20110110A (es) 2011-04-28
ZA201101198B (en) 2012-05-30
MY156305A (en) 2016-01-29
WO2010013823A3 (en) 2010-04-15
DOP2013000172A (es) 2013-11-15
DOP2011000033A (es) 2011-04-15
AU2009277443A1 (en) 2010-02-04
ES2660962T3 (es) 2018-03-26
US20130261156A1 (en) 2013-10-03
IL228817A0 (en) 2013-12-31
EP2309985B1 (en) 2018-03-14
EA201201451A1 (ru) 2013-07-30
BRPI0916689A2 (pt) 2015-11-17
US20110124687A1 (en) 2011-05-26
GEP20146166B (en) 2014-09-25
PE20110591A1 (es) 2011-09-15
CA2732243A1 (en) 2010-02-04
WO2010013823A2 (en) 2010-02-04
JP2013047239A (ja) 2013-03-07
CL2011000170A1 (es) 2011-06-10
MA32556B1 (fr) 2011-08-01

Similar Documents

Publication Publication Date Title
PE20141585A1 (es) Composicion farmaceutica estabilizada a base de un compuesto no petidico
ES2508290T3 (es) Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
BRPI0923728A2 (pt) "método de preparação de compostos de di-hidroindeno amida, suas composições farmacêuticas contendo esses compostos e uso como inibidor de proteína quinase".
CR10027A (es) Nuevos derivados de pirrol fusionado
CR20120058A (es) Composiciones nuevas de 1 - [2 - (2,4-dimetil-fenilsulfanil)-fenil] piperazina
CR7548A (es) Derivados de triazole como antagonistas del receptor de tachykinin
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
PE20130239A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
EA201071218A1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
BR112012014721A2 (pt) composição de hormônio do crescimento
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
CO6612226A2 (es) Tableta
CO6361855A2 (es) Derivados de 7-hidroxi-benzoimidazol-4-il-,etanona e inhibidores de cinasa que enlaza pdz que contienen los mismos
MX382264B (es) Composiciones que comprenden amlodipina y bisoprolol.
CO6351721A2 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
MX364610B (es) Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida.
EA201070194A1 (ru) Стабильная жидкая фармацевтическая композиция на основе тразодона
MA32628B1 (fr) Agents antifongiques
TR201803451T4 (tr) Olmesartan formülasyonlari.
UA98642C2 (ru) Способ получения стабильных при хранении растворов экстрактов пеларгонии
MX381175B (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
BRPI0416027A (pt) sistema de entrega de drogas para inibidores de bomba de prótons e processo resultante
UY28152A1 (es) (4-(3-aminometilfenil)piperidin-1-il)-(5-(2-fluorofeniletinil)furan-2-il)-metanona como inhibidor de triptasa de mastocitos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal